Date:3/3/2010

ges related to product recall(k) 604 - 604 - ------------------------------------------------------------------------- ------------------------------------------------------------------------- Adjusted EBITDA $ 6,868 $ 10,332 $ 49,311 $ 37,109 ------------------------------------------------------------------------- ------------------------------------------------------------------------- RECONCILIATION OF GAAP NET LOSS TO NON-GAAP ADJUSTED NET LOSS (Unaudited) Three months ended Year ended (in thousands December 31, December 31, U.S.$) 2009 2008 2009 2008 ------------- ------------- ------------- ------------- GAAP - net loss (15,633) (76,963) (22,868) (741,176) Non recurring revenue(a) (53) (352) (25,556) (910) Technology acquisition related charge(c) 500 313 1,866 3,438 Non-recurring supply/distribution agreement termination costs(b) - - - 500 Non-recurring restructuring related charges(b) (309) 1,583 3,820 10,407 Stock based compensation expense(d) 408 458 1,579 2,436 Litigation related charges(g) 684 177 3,297 2,670 Write-down of investments, goodwill & other long-lived assets(i) 3,090 62,532 3,090 674,555 Write-down and other deferred financing charges(f) 712 4,224 3,431 19,445 Forei
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter